News: Monday May 10, 4:13 pm Eastern Time
Company Press Release
Endovasc Ltd. Inc. Announces Filing of Two
New Patents
MONTGOMERY, Texas--(BW HealthWire)--May 10, 1999--Endovasc Ltd.
Inc. (OTC BB:ENDV - news) today announced the filing of two (2) new patent
applications to further broaden its two issued and one notice of allowance patents covering the use of prostaglandin
and its metabolites in treating (1) dysfunctions relating to angioplasty, and (2) biodegradable PGE-1 containing stent
coatings. The newly filed applications further elaborate the broad field of use, owned by Endovasc, for
prostaglandins and their use in covering bone stimulating coatings for a prosthesis such as hip, knee (and other
prosthesis), and biodegradable liposomes placed via a catheter within a blood vessel wall to enhance the treatment of
restenosis.
The company spokesman, Dr. David P. Summers, said, ''We have entered into business discussions with several
large companies that are looking for proprietary interests in the markets they serve; and this intellectual property is
the mainstay of the biotechnology business. We have 'grandfathered' our prostaglandin patents back to 1989 and will
continue to use our patents as brick and mortar to produce state-of-the-art products for our $2 billion market.''
About the company:
Endovasc Ltd. Inc. is a biopharmaceutical company using liposomal drug delivery for products that have already
shown safety and efficacy in the generic form. The company's products and processes are covered by patents and
trade secrets for competing in a $2 billion market.
The foregoing statements are made under the ''Safe Harbor'' Private Securities Litigation Reform Act of 1995 and
may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this
release.
Contact:
PMR & Associates, Encinitas
760/635-8695
E-mail: pmrandco@aol.com
More Quotes and News:
Endovasc Limited Inc (OTC BB:ENDV - news)
Related News Categories: biotech, medical/pharmaceutical
Help
Copyright © 1999 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms
of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution
of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina public database,
redistributing via a computer network or in a printed form.
See our Important Disclaimers and Legal Information. |
